Didymin by suppressing NF-κB activation prevents VEGF-induced angiogenesis in vitro and in vivo.
Angiogenesis Inducing Agents
/ pharmacology
Angiogenesis Inhibitors
/ pharmacology
Animals
Cell Adhesion Molecules
/ metabolism
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cells, Cultured
Flavonoids
/ pharmacology
Glycosides
/ pharmacology
Human Umbilical Vein Endothelial Cells
/ drug effects
Humans
Male
Mice, Inbred C57BL
NF-kappa B
/ antagonists & inhibitors
Neovascularization, Physiologic
/ drug effects
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
Vascular Endothelial Growth Factor A
/ pharmacology
Angiogenesis
Didymin
HUVEC
Neovascularization
VEGF
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
08
05
2018
revised:
05
11
2018
accepted:
07
01
2019
pubmed:
12
1
2019
medline:
1
8
2019
entrez:
12
1
2019
Statut:
ppublish
Résumé
Although didymin, a dietary flavonoid glycoside from citrus fruits, known to be a potent antioxidant with anti-cancer activities, its role in angiogenesis is not known. In this study, we examined the effect of didymin on VEGF-induced angiogenesis in vitro and in vivo models. Our results suggest that treatment of human umbilical vein endothelial cell (HUVECs) with didymin significantly prevented the VEGF-induced cell proliferation, migration, and invasion. Further, didymin significantly prevented the VEGF-induced endothelial tube formation in culture. Didymin also attenuated the VEGF-induced generation of ROS, activation of NF-κB and the expression of adhesion molecules such as VCAM-1, ICAM-1, and E-selectin in HUVECs. Further, didymin also prevented the VEGF-induced microvessel sprouting in ex vivo mouse aortic rings. Most importantly, didymin significantly prevented the invasion of endothelial cells and formation of blood capillary-like structures in Matrigel plug model of angiogenesis in mice. Thus, our results suggest a novel antiangiogenic efficacy of didymin in addition to its reported anti-cancer properties, which warrant further development of this agent for cancer therapy.
Identifiants
pubmed: 30634049
pii: S1537-1891(18)30168-X
doi: 10.1016/j.vph.2019.01.002
pii:
doi:
Substances chimiques
Angiogenesis Inducing Agents
0
Angiogenesis Inhibitors
0
Cell Adhesion Molecules
0
Flavonoids
0
Glycosides
0
NF-kappa B
0
Reactive Oxygen Species
0
Vascular Endothelial Growth Factor A
0
didymin
0
Types de publication
Journal Article
Langues
eng
Pagination
18-25Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.